DOD Duchenne Muscular Dystrophy, Idea Development Award

The Department of Defense’s Duchenne Muscular Dystrophy Research Program (DMDRP) is offering the Idea Development Award (IDA) for FY25 to support innovative, high-risk research that aims to improve outcomes for individuals with Duchenne muscular dystrophy (DMD). The program encourages applications with well-formulated hypotheses grounded in solid scientific rationale, particularly from early-career and transitioning investigators. The funding total is approximately $1.68 million, allowing up to three awards with a cap of $350,000 for direct costs over a maximum of two years. Applications are due in July and August 2025, with a two-step submission process involving a pre-application and a full application. Eligibility extends to a wide range of organizations, including academic institutions and for-profit entities, while emphasizing collaboration among experienced researchers. The program specifically seeks studies targeting the primary pathology of DMD, particularly innovative therapeutic strategies. The award mechanism excludes clinical trials, focusing instead on fundamental and preparatory research. The application review process consists of peer and programmatic evaluations based on innovation, impact, research strategy, feasibility, personnel qualifications, and environmental considerations. This initiative underlines the U.S. Army's commitment to advancing DMD research for both military families and the public.